Q-omics provides the consensus-scored ZNF768 profile across patient tissues and cancer cell-line models. ZNF768 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ZNF768 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, ZNF768 protein abundance shows 24,379 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, KIRP, and LSCC as cancer lineages where ZNF768 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF768 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF768 survival associations across molecular data types. ZNF768 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF768 RNA expression–survival associations across cancer types. High ZNF768 expression shows unfavorable associations in LIHC, ACC, KIRP, LGG and COAD, but favorable associations in KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ZNF768 RNA expression.
This table summarizes ZNF768 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF768. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF768 shows higher tumor expression in KIRP, KIRC, LIHC, LUAD, HNSC and LUSC. The KIRP box plot shows higher ZNF768 RNA expression in tumor versus normal tissue (log2 FC = +1.227, t-test p < 0.001).
This table shows molecular features associated with ZNF768 in patient tissues and cancer cell lines. In patient samples, ZNF768 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF768 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
